Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford, in partnership with the Royal College of Surgeons (RCS) and the Rosetrees Trust, are delighted to announce two new professorial posts.

From left to right: Ann Berger from Rosetrees Trust, Richard Ross from Rosetrees Trust, Professor David Beard, Professor Michael Douek and Vineeth Rajkumar from Rosetrees Trust

Professor David Beard is the newly appointed Director of the RCS Surgical Intervention Trials Unit (SITU) NDORMS and Professor Michael Douek, the newly appointed Director of the RCS SITU Nuffield Department of Surgical Sciences (NDS).

The appointments will add to growth in surgical clinical research activity, both nationally and internationally. Professors Beard and Douek will work closely with the RCS Surgical Trials Initiative, other RCS Professorial Chairs, RCS Surgical Trials Centres and Surgical Specialty Leads, to further clinical research activity across the UK.

Commenting on the new appointments Professor Derek Alderson, President of the Royal College of Surgeons, said:

“The RCS is very pleased to be working with the University of Oxford and the Rosetrees Trust, who are long-term supporters of research at the RCS. Together we will continue our commitment to improve clinical research in all areas and ultimately provide patients with an increased level of care.”

The appointments will act as key links between Surgical Trails Centres and National Clinical Research Networks to aid in the development of new trials, establish clinical networks and develop and deliver innovative trials.

Richard Ross, Chairman of Rosetrees Trust, said:

“Rosetrees is delighted to fund these positions jointly with the University of Oxford and the RCS surgical trials initiative. Rosetrees hopes the RCS tradition of creating awards for ground-breaking research will be reflected in the work these two outstanding Professors will undertake in the coming years and we look forward to a long and fruitful association.”

Now with frameworks, methodology and surgical trial units in the UK all well established, this next phase will see further developments linked to the Future of Surgery, automation, big data, global health and the further advances addressing the methodological nuances of evaluating a complex intervention such as surgery. - Profesor David Beard

Commenting on the new appointments, Head of Department for NDORMS Professor Andrew Carr said:

“We are very excited to welcome both Professor Douek and Professor Beard to SITU and the Botnar Research Centre as the Rosetrees RCS Directors. They both have a wealth of valuable experience in surgical trials which will allow them to successfully lead and further expand our work in this critical area of research activity, for the benefit of surgical patients in the UK and worldwide.”

Speaking on his appointment, Professor Beard said:

“I am honoured and delighted to be appointed to this new role. The Rosetrees Foundation have been an essential ingredient in RCS’ surgical evaluation initiative for several years. Their generous support and insight has been a leading factor in the overall success of the surgical trial development in this country.

“The added formal connection with the Medical Sciences Division here at Oxford creates a further formidable partnership. Now with frameworks, methodology and surgical trial units in the UK all well established, this next phase will see further developments linked to the Future of Surgery, automation, big data, global health and the further advances addressing the methodological nuances of evaluating a complex intervention such as surgery.

“While the need for quality trials remains ever present, consideration must extend to all stakeholders. Naturally the welfare of patients is foremost, but some balance will be required for the needs of surgeons, clinicians, practitioners, innovative industry partners and healthcare commissioners.

“The surgical evaluation team may be a relatively ‘new kid’ on the block in evaluative science, but its role will become increasingly important for healthcare provision of the future. I very much look forward to being a part of that exciting process.”

Of his appointment, Professor Douek said:

“I am passionate about surgical research and very excited to take on this role. I am driven by the conviction that novel surgical techniques and clinical devices should be evaluated with the same rigour and governance as established in drug clinical trials”.

News item courtesy of the Royal College of Surgeons

Funders

            Royal College of Surgeons logo

Rosetrees Trust logo

 

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.